Following the introduction of targeted agents beginning in the late 1990s, there is a common misconception that the use of older cancer therapies, such as radiation, is on the decline.
Earthquake Highlights Unmet Need for Treating Radiation Sickness
March 13, 2011 By 4 Comments
Few treatment options exist for exposure to high doses of ionizing radiation over a short period of time, which would be expected following the meltdown of a nuclear reactor and other scenarios.
Monoclonal Antibody Companies Command Premiums
July 11, 2010 By Leave a Comment
Monoclonal antibodies, which have been approved for immunological, anti-infective, ophthalmic, cancer and other categories, represent one of the most successful therapeutic drug classes. Ten monoclonal antibodies have been approved for cancer therapy alone, including three blockbuster products sold by the Roche Group (RHHBY) – Avastin® [bevacizumab], Rituxan® [rituximab], and Herceptin® [trastuzumab] that collectively represented nearly [...]
Biotech Deal Activity Declines…The Pause that Refreshes?
January 14, 2010 By 1 Comment
* MD Becker Partners reporting live from the JP Morgan Healthcare Conference This week, nearly 6,500 registrants gathered in San Francisco, California for the JP Morgan Healthcare Conference to hear 25-minute presentations from 338 life science companies. For industry executives and investors, the annual event serves as a good barometer for the rest of the [...]
Follow MD Becker Partners